Veoza (fezolinetant)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- fezolinetant
- Company
- Astellas Pharma Europe B.V.
- Status
- Authorised
- Therapeutic area
- Menopause; Hot Flashes
- CHMP opinion
- Thu 12 Oct 2023
- EU approval
- Thu 07 Dec 2023
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005851
- ATC
- G02CX06
- Official record
- www.ema.europa.eu
Indication
Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Regulatory milestones
No milestones recorded in the last year.
Follow Veoza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.